EDEsther Decabooter

Esther Decabooter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Esther Decabooter has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Patient specific quality assurance: The final safety net in radiotherapy

    by Esther Decabooter, Marion Essers, Eduard Gershkevitsh, Mohammad Hussein, Stephen F. Kry, Joerg Lehmann, Wouter van Elmpt, David Thwaites


  • Open Access

    Data-driven patient treatment optimization: a large-scale retrospective analysis of pretreatment and in vivo patient-specific quality assurance

    by Esther Decabooter, Sebastiaan Nijsten

    As radiotherapy techniques become increasingly complex, patient-specific quality assurance (PSQA) must evolve to detect a broad spectrum of potential failure modes across the treatment chain. This study presents a five-year retrospective analysis of an integrated PSQA framework implemented at Maastro Clinic, combining secondary dose calculations, log-file-based verification, and Electronic Portal Dosimetry (EPD) in both pretreatment and in vivo workflows. The performance of this framework was evaluated in the context of high-priority failure modes identified by the AAPM-ESTRO Failure Mode and Effects Analysis (FMEA).A total of 18,558 treatment plans were analyzed. Pretreatment secondary dose calculations identified algorithm-specific limitations, as well as discrepancies arising from unmodeled immobilization devices in the treatment planning system (TPS) and dose uncertainties due to small fields with jaw tracking. Log file and EPD pretreatment PSQA revealed additional plan transfer and deliverability issues, including rare cases of overmodulation. In vivo dose verification of 13,658 Cone Beam CT (CBCT) based fractions demonstrated that 21.19% of treatment plans exhibited at least one interfractional deviation, primarily related to patient setup, anatomical changes, or CBCT limitations. Intrafractional motion was detected in 0.50% of plans using in vivo EPD.Mapping these findings to the FMEA revealed that the combined PSQA framework effectively detected many failure modes, though limitations remained for errors rooted in TPS input data when also used for fitting PSQA dose calculation algorithms. The results underscore the value of multimodal PSQA and highlight opportunities for future enhancement e.g. using more clinically relevant evaluation metrics and dose accumulation of PSQA results.

  • Open Access

    Survey on fan-beam computed tomography for radiotherapy: Current implementation and future perspectives of motion management and surface guidance devices

    by Chrysi Papalazarou, Sima Qamhiyeh, Robert Kaatee, Joke De Rouck, Esther Decabooter, Guido C. Hilgers, Koen Salvo, Jacobus van Wingerden, Hilde Bosmans, Brent van der Heyden, et al.


  • Open Access

    Survey on fan-beam computed tomography for radiotherapy: Imaging for dose calculation and delineation

    by Esther Decabooter, Guido C. Hilgers, Joke De Rouck, Koen Salvo, Jacobus Van Wingerden, Hilde Bosmans, Brent van der Heyden, Sima Qamhiyeh, Chrysi Papalazarou, Robert Kaatee, et al.


  • Open Access

    Clinical benefit of range uncertainty reduction in proton treatment planning based on dual-energy CT for neuro-oncological patients

    by Vicki Trier Taasti, Esther Decabooter, Daniëlle Eekers, Inge Compter, Ilaria Rinaldi, Marta Bogowicz, Tim van der Maas, Esther Kneepkens, Jacqueline Schiffelers, Cissy Stultiens, et al.

    Objective: Several studies have shown that dual-energy CT (DECT) can lead to improved accuracy for proton range estimation. This study investigated the clinical benefit of reduced range uncertainty, enabled by DECT, in robust optimisation for neuro-oncological patients. Methods: DECT scans for 27 neuro-oncological patients were included. Commercial software was applied to create stopping-power ratio (SPR) maps based on the DECT scan. Two plans were robustly optimised on the SPR map, keeping the beam and plan settings identical to the clinical plan. One plan was robustly optimised and evaluated with a range uncertainty of 3% (as used clinically; denoted 3%-plan); the second plan applied a range uncertainty of 2% (2%-plan). Both plans were clinical acceptable and optimal. The dose–volume histogram parameters were compared between the two plans. Two experienced neuro-radiation oncologists determined the relevant dose difference for each organ-at-risk (OAR). Moreover, the OAR toxicity levels were assessed. Results: For 24 patients, a dose reduction >0.5/1 Gy (relevant dose difference depending on the OAR) was seen in one or more OARs for the 2%-plan; e.g. for brainstem D0.03cc in 10 patients, and hippocampus D40% in 6 patients. Furthermore, 12 patients had a reduction in toxicity level for one or two OARs, showing a clear benefit for the patient. Conclusion: Robust optimisation with reduced range uncertainty allows for reduction of OAR toxicity, providing a rationale for clinical implementation. Based on these results, we have clinically introduced DECT-based proton treatment planning for neuro-oncological patients, accompanied with a reduced range uncertainty of 2%. Advances in knowledge: This study shows the clinical benefit of range uncertainty reduction from 3% to 2% in robustly optimised proton plans. A dose reduction to one or more OARs was seen for 89% of the patients, and 44% of the patients had an expected toxicity level decrease.


  • Quality assurance of scanned proton beams at different gantry angles using an ionization chamber array in a rotational phantom

    by Esther Decabooter, Erik Roijen, Jonathan Martens, Mirko Unipan, Geert Bosmans, Gloria Vilches-Freixas


  • Open Access

    Operation and calibration of the novel PTW 1600SRS detector for the verification of single isocenter stereotactic radiosurgery treatments of multiple small brain metastases

    by Esther Decabooter, Ans Cc Swinnen, Michel C Öllers, Fabian Göpfert, Frank Verhaegen

    Objectives: The aim of this work was to evaluate the operation of the 1600SRS detector and to develop a calibration procedure for verifying the dose delivered by a single isocenter stereotactic radiosurgery (SRS) treatment of small multiple brain metastases (BM). Methods: 14 clinical treatment cases were selected with the number of BM ranging from 2 to 11. The dosimetric agreement was investigated between the calculated and the measured dose by an OCTAVIUS 1600SRS array detector in an OCTAVIUS 4D phantom equipped with dedicated SRS top. The cross-calibration procedure deviated from the manufacturer’s as it applied field sizes and dose rates corresponding to the volumetric modulated arc therapy segments in each plan. Results: Measurements with a plan specific cross-calibration showed mean ± standard deviation (SD) agreement scores for cut-off values 50%, 80%, 95%, of 98.6 ± 1.7%, 96.5 ± 4.6%, 97.3 ± 4.4% for the 6 MV plans respectively, and 98.6 ± 1.5%, 96.6 ± 4.0% 96.4 ± 6.3%, for the 6 MV flattening filter free (FFF) plans respectively. Using the default calibration procedure instead of the plan specific calibration could lead to a combined systematic dose offset of 4.1% for our treatment plans. Conclusion: The 1600SRS detector array with the 4D phantom offers an accurate solution to perform routine quality assurance measurements of single isocenter SRS treatments of multiple BM. This work points out the necessity of an adapted cross-calibration procedure. Advances in knowledge: A dedicated calibration procedure enables accurate dosimetry with the 1600SRS detector for small field single isocenter SRS treatment of multiple brain metastases for a large amount of BM.


  • Beam commissioning of the first compact proton therapy system with spot scanning and dynamic field collimation

    by Gloria Vilches-Freixas, Mirko Unipan, Ilaria Rinaldi, Jonathan Martens, Erik Roijen, Isabel P. Almeida, Esther Decabooter, Geert Bosmans

    Objectives: To describe the measurements and to present the results of the beam commissioning and the beam model validation of a compact, gantry-mounted, spot scanning proton accelerator system with dynamic layer-by-layer field collimation. Methods: We performed measurements of depth dose distributions in water, spot and scanned field size in air at different positions from the isocenter plane, spot position over the 20 × 20 cm2 scanned area, beam monitor calibration in terms of absorbed dose to water and specific field collimation measurements at different gantry angles to commission the system. To validate the beam model in the treatment planning system (TPS), we measured spot profiles in water at different depths, absolute dose in water of single energy layers of different field sizes and inversely optimised spread-out Bragg peaks (SOBP) under normal and oblique beam incidence, field size and penumbra in water of SOBPs, and patient treatment specific quality assurance in homogeneous and heterogeneous phantoms. Results: Energy range, spot size, spot position and dose output were consistent at all gantry angles with 0.3 mm, 0.4 mm, 0.6 mm and 0.5% maximum deviations, respectively. Uncollimated spot size (one sigma) in air with an air-gap of 10 cm ranged from 4.1 to 16.4 mm covering a range from 32.2 to 1.9 cm in water, respectively. Absolute dose measurements were within 3% when comparing TPS and experimental data. Gamma pass rates >98% and >96% at 3%/3 mm were obtained when performing 2D dose measurements in homogeneous and in heterogeneous media, respectively. Leaf position was within ±1 mm at all gantry angles and nozzle positions. Conclusions: Beam characterisation and machine commissioning results, and the exhaustive end-to-end tests performed to assess the proper functionality of the system, confirm that it is safe and accurate to treat patients. Advances in knowledge: This is the first paper addressing the beam commissioning and the beam validation of a compact, gantry-mounted, pencil beam scanning proton accelerator system with dynamic layer-by-layer multileaf collimation.